= per oral; UA = urinalysis; SCR = screening; VC = vital capacity. Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 36 5.2 STUDY PROCEDURES 5.2.1 Screening Period (28 days prior to first study dose) Before screening assessments are conducted, the subject must be given a complete explanation of the purpose and evaluations of the study. Subsequently, the subject must sign and receive a copy of an informed consent for m (ICF) that was approved by the institutional review board (IRB) and an authorization for use and disclosure of protected health information (PHI) before any study -specific procedure is performed. An original signed consent form will be retained in the subject’s source documentation at the site, and a copy will be provided for the subject to take home. Screening will occur within 28 days before treatment administration. Potential subjects will be evaluated for entry into the study according to the stated inclusion and exclusion criteria. Individuals who are identified during this screening as not eligible for study enrollment need not complete all screening procedures. The reason for ineligible status will be documented. The following evaluations will be performed to assess the subject’s eligibility for the study: • Medical history, including history of carcinoma treatment • Medication history over the past 28 days, including prescription and over-the- counter medications, herbs, vitamins, minerals, and prophylactic vaccines • Baseline signs and symptoms • Physical examination • ECOG performance status • Vital signs (BP, pulse, respiratory rate, temperature), height, weight, and pulse oxygen saturation • Resting 12- lead electrocardiogram • Pulmonary function tests: VC , FVC and FEV 1 Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 37 • Clinical hematology: complete blood count (CBC) with differential ANC and platelet count • Serum chemistry: sodium, potassium, chloride, bicarbonate, glucose, BUN, creatinine, lactate dehydrogenase (LDH) , ALT, AST, alkaline phosphatase, bilirubi n (total, direct, indirect), total protein, albumin, calcium, magnesium, uric acid, and phosphate • Coagulation panel: prothrombin time (PT), international normalized ratio of prothrombin time (INR) , and activated partial thromboplastin time (APTT) • Virology screen if one has not been done within 14 days before screening: HIV antibody, hepatitis B surface antigen, and hepatitis C antibody • Urinalysis (UA): bilirubin, blood, glucose, ketones, leukocytes, nitrite, pH, protein, and specific gravity • Creatinine clearance calculated by Cockcroft -Gault formula = {[(140- age) x weight in kilograms] x [0.85 if female]}/[72 x creatinine in mg/dL] • CD4 count • Tumor markers: mesothelin, CA-125 and plasma osteopontin. Other markers may also be evaluated .